Cannabis use disorder

[8] The sedating and anxiolytic properties of tetrahydrocannabinol (THC) in some users might make the use of cannabis an attempt to self-medicate personality or psychiatric disorders.[10] Cannabis users have shown decreased reactivity to dopamine, suggesting a possible link to a dampening of the reward system of the brain and an increase in negative emotion and addiction severity.[14] Cannabis dependence develops in about 9% of users, significantly less than that of heroin, cocaine, alcohol, and prescribed anxiolytics,[15] but slightly higher than that for psilocybin, mescaline, or LSD.Longitudinal studies over a number of years have enabled researchers to track aspects of social and psychological development concurrently with cannabis use.[25] The main factors in Australia, for example, related to a heightened risk for developing problems with cannabis use include frequent use at a young age; personal maladjustment; emotional distress; poor parenting; school drop-out; affiliation with drug-using peers; moving away from home at an early age; daily cigarette smoking; and ready access to cannabis.The researchers concluded there is emerging evidence that positive experiences to early cannabis use are a significant predictor of late dependence and that genetic predisposition plays a role in the development of problematic use.[26] A number of groups have been identified as being at greater risk of developing cannabis dependence and, in Australia have been found to include adolescent populations, Aboriginal and Torres Strait Islanders and people with mental health conditions.According to a study completed by Bill Sanders, influence from friends, difficult household problems, and experimentation are some of the reasons why this population starts to smoke cannabis.[6] Screening and brief intervention sessions can be given in a variety of settings, particularly at doctor's offices, which is of importance as most cannabis users seeking help will do so from their general practitioner rather than a drug treatment service agency.[55] In 2006, the Wisconsin Initiative to Promote Healthy Lifestyles implemented a program that helps primary care physicians identify and address marijuana use problems in patients.[56] As of 2023, there is no medication that has been proven effective for treating cannabis use disorder, research is focused on three treatment approaches: agonist substitution, antagonist, and modulation of other neurotransmitter systems.[57] For the treatment of the withdrawal/negative affect symptom domain of cannabis use disorder, medications may work by alleviating restlessness, irritable or depressed mood, anxiety, and insomnia.[58] Atomoxetine has also shown poor results, and is as a norepinephrine reuptake inhibitor, though it does increase the release of dopamine through downstream effects in the prefrontal cortex (an area of the brain responsible for planning complex tasks and behavior).[58] Venlafaxine, a serotonin–norepinephrine reuptake inhibitor, has also been studied for cannabis use disorder, with the thought that the serotonergic component may be useful for the depressed mood or anxious dimensions of the withdrawal symptom domain.[58] It is worth noting that venlafaxine is sometimes poorly tolerated, and infrequent use or abrupt discontinuation of its use can lead to withdrawal symptoms from the medication itself, including irritability, dysphoria, and insomnia.[58] Baclofen, a GABAB receptor agonist and antispasmodic medication, has been found to reduce cravings but without a significant benefit towards preventing relapse or improving sleep.[58] Zolpidem, a GABAA receptor positive allosteric modulator and "z-drug" medication, has shown some efficacy in treating insomnia due to cannabis withdrawal, though there is a potential for misuse.[6] Topiramate, an antiepileptic drug, has shown mixed results in adolescents, reducing the volume of cannabis consumption without significantly increasing abstinence, with somewhat poor tolerability.[58] Quetiapine, an atypical antipsychotic, has been shown to treat cannabis withdrawal related insomnia and decreased appetite at the expense of exacerbating cravings.[50] Heavy cannabis use has been associated with impaired cognitive functioning; however, its specific details are difficult to elucidate due to the potential use of additional substances of users, and lack of longitudinal studies.
blood flowprefrontal cortexSpecialtyAddiction medicinePsychiatrySymptomsDependencywithdrawalanxietyirritabilitydepressiondepersonalizationrestlessnessinsomniadreamsgastrointestinaldecreased appetiteRisk factorsAdolescencePsychotherapyMedicationpsychiatric disorderDiagnostic and Statistical Manual of Mental DisordersICD-10cannabiscommon misconceptionanxiety disordersdependentsedatinganxiolytictetrahydrocannabinolpersonalitypsychiatric disorderspharmacokineticpharmacodynamicdopaminereward systemnegative emotionaddictiontolerancecannabinoid receptorheroincocainealcoholanxiolyticspsilocybinmescalinedysphoriarhythmic movement disorderpersonality disordersnightmaresadverse childhood experiencesAboriginalTorres Strait Islandersendocannabinoid systemsocial anxietysuicidalitysmokingAmerican College of Obstetricians and Gynecologistssmoking cannabis during pregnancyInternational Classification of Diseases10th revisionTimeline Follow-BackopioidPsychological interventioncognitive behavioral therapymotivational enhancement therapycontingency managementtwelve-step programsMarijuana AnonymousAlcoholics AnonymousNarcotics AnonymousBupropionnorepinephrine–dopamine reuptake inhibitorAtomoxetinenorepinephrine reuptake inhibitorVenlafaxineserotonin–norepinephrine reuptake inhibitorclinical trialMirtazapineserotoninnorepinephrineBuspironeserotonin 5-HT1A receptorpartial agonistFluoxetineselective serotonin reuptake inhibitorantidepressantsVilazodonevalproateBaclofenGABAB receptorantispasmodicZolpidemGABAA receptorEntacaponeTopiramateantiepilepticGabapentinnicotine replacement therapynicotine addictionDronabinolα2-adrenergic receptorlofexidineNabiloneharm reductionNabiximolscannabidiolCB1 receptorantagonistrimonabantNaltrexoneμ-opioid receptorN-acetylcysteineLithiummood stabilizerQuetiapineatypical antipsychoticOxytocinCB1 receptor antagonistsNational Survey on Drug Use and HealthLa Guardia CommitteeMedical cannabisQuitting smokingThe New York TimesInnovations in Clinical NeuroscienceDavid McDowellGuilford PressBibcodeAmerican Psychiatric AssociationReinforcementdependenceNicotineBehavioralGamblingShoppingPalatable foodIntercoursePornographyInternet addiction disorderInternet sex addictionVideo game addictionDigital media addictionsTranscriptionalNF-κBEpigeneticG9a-like proteinHDAC10Physical dependencePsychological dependenceAlcoholismAmphetamineBarbiturateBenzodiazepineCaffeineTanning dependenceTreatment and managementAlcohol detoxificationDrug detoxificationRelapse preventionCommunity reinforcement approach and family trainingMotivational interviewingMotivational therapyDrug rehabResidential treatment centerHeroin-assisted treatmentIntensive outpatient programMethadone maintenanceSmoking cessationTobacco cessation clinics in IndiaTwelve-step programAddiction recovery groupsList of twelve-step groupsDrug checkingReagent testingLow-threshold treatment programsManaged alcohol programModeration ManagementNeedle exchange programResponsible drug useStimulant maintenanceSupervised injection siteTobacco harm reductionAllen CarrDiscrimination against drug addictsDopamine dysregulation syndromeCognitive controlInhibitory controlMotivational salienceSober companionOutline of cannabisRecreational and medical applicationsIndustrial applicationsAutoflowering cannabisindicaruderalissativaChemical defenses in CannabisConsumptionConversion of CBD to THCCultivationGlossarymarijuanaStrainsSynthetic cannabisCannabis use and traumaCannabis product testingHistoryIn the USMedical cannabis cardReligious and spiritual useChaliceDrug testingHanfparadeList of hemp diseasesList of hemp productshempcretejewelryrolling paperList of hemp varietiesHemp for VictoryHemp Industries AssociationThe Emperor Wears No ClothesCannabis edibleCannabis teaCannabis smokingVaporizingCannabis concentrateEssential oilCharasHashishHash oilTinctureMarihuana prensadaPhytocannabinoidsdelta-8-THCdelta-10-THCEffectsAmotivational syndromeCannabis in pregnancyCannabinoid hyperemesis syndromeClinical endocannabinoid deficiency syndromeEntourage effectImpaired drivingTime perceptionLong-term effectsOccupational health concernsMedical cannabis researchCultureBudtenderCannabis by CountryCookbooksEtiquetteCannabis Social ClubHead shopCannabis CultureColumnsCompetitionsList of cannabis hoaxesStoner filmHigh TimesReligionRestaurantsSportsOperation OvergrowSmoke-inStoner TVVideo gamesCannabis rightsDagga CoupleGLM IndiaFranceICEERSAdult lifetime use by countryAnnual use by countryActivistsCapital punishment for cannabis traffickingEffects of legalized cannabisGlobal Marijuana MarchLegality of cannabisInternationallyRegulatory agencies1961 Single Convention on Narcotic Drugs1971 Vienna Convention on Psychotropic Substances1998 UN Convention on Illicit TraffickingLegal history in the United StatesMarihuana Tax Act of 1937Timeline of cannabis lawRescheduling of cannabis in 20202018 Cannabis ActGerman cannabis control billLaw No. 19172Legalization of non-medical cannabis in the USRescheduling per the Controlled Substances ActHemp Farming Act of 2018Cannabis political partiesof the USof Minnesotaof SpainList of British politicians who have acknowledged cannabis useList of American politicians who have acknowledged cannabis useKer v. CaliforniaLeary v. United StatesKyllo v. United StatesGonzales v. RaichADPF 187Drug liberalizationImpact of the COVID-19 pandemic on the cannabis industryCannabinoid receptor antagonistEndocannabinoid enhancerEndocannabinoid reuptake inhibitorPsychoactivesubstance-related disordersSubstance intoxicationDrug overdoseSubstance-induced psychosisNeonatal withdrawalPost-acute-withdrawal syndromeSubstance abuseSubstance dependencePolysubstance dependenceCombined drug intoxicationCardiovascular diseasesAlcoholic cardiomyopathyAlcohol flush reactionGastrointestinal diseasesAlcoholic liver diseaseAlcoholic hepatitisZieve's syndromeAuto-brewery syndromeEndocrine diseasesAlcoholic ketoacidosisNervous system diseasesAlcohol-related dementiaAlcohol intoxicationHangoverNeurological disordersAlcoholic hallucinosisAlcoholic polyneuropathyAlcohol-related brain damageAlcohol withdrawal syndromeDelirium tremensFetal alcohol spectrum disorderKorsakoff syndromeMarchiafava–Bignami diseasePositional alcohol nystagmusWernicke–Korsakoff syndromeWernicke encephalopathyRespiratory tract diseasesAlcohol-induced respiratory reactionsAlcoholic lung diseaseBinge drinkingCaffeine-induced anxiety disorderCaffeine-induced psychosisCaffeine-induced sleep disorderCaffeinismCaffeine dependenceIntravenous marijuana syndromeCocaine intoxicationPrenatal cocaine exposureCocaine-induced midline destructive lesionsCocaine dependenceHallucinogenAcute intoxication from hallucinogens (bad trip)Hallucinogen persisting perception disorderGreen Tobacco SicknessNicotine poisoningNicotine withdrawalNicotine dependenceOpioidsOpioid overdoseOpioid withdrawalOpioid-induced hyperalgesiaOpioid-induced endocrinopathyOpioid-induced constipationOpioid use disorderSedativehypnoticKindling (sedative–hypnotic withdrawal)Benzodiazepine overdoseBenzodiazepine withdrawalBenzodiazepine use disorderBenzodiazepine dependenceBarbiturate overdoseBarbiturate dependenceStimulantsStimulant psychosisAmphetamine dependenceVolatile solventSudden sniffing death syndromeToluene toxicityChronic solvent-induced encephalopathyInhalant abuseAnabolic-androgenic steroidsAnabolic-androgenic steroids abuseChocolate